A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III (APOC3) a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pollin, Toni I., Damcott, Coleen M., Shen, Haiqing, Ott, Sandra H., Shelton, John, Horenstein, Richard B., Post, Wendy, McLenithan, John C., Bielak, Lawrence F., Peyser, Patricia A., Mitchell, Braxton D., Miller, Michael, O'Connell, Jeffrey R., Shuldiner, Alan R.
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2673993/
https://ncbi.nlm.nih.gov/pubmed/19074352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1161524
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares